Clinical Trial

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Study acronym: MUKseven
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is determining whether the addition of cyclophosphamide to pomalidomide and dexamethasone improves progression free survival in patients with relapsed refractory myeloma (RRMM) compare to pomalidomide and dexamethasone alone. Patients will be randomised on a 1:1 basis to receive CPD or Pd. Treatment will be continued until disease progression or unacceptable toxicity.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2015-03-29; most recent amendment 2024-12-04.
Status change: Recruiting → Active, Not Recruiting 2020-01-23
Status change: Not Yet Recruiting → Recruiting 2016-05-11
Trial Details
NCT Number NCT02406222
Lead Sponsor University of Leeds
Collaborators: Myeloma UK, Celgene
Conditions Multiple Myeloma
Enrollment 124 participants
Start Date 2016-03
Primary Completion 2022-12 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2024-12-05